Enitociclib
Based on 2 publication(s) in Google Scholar
Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 1610408-97-3
- Formule: C19H18F2N4O2S
- Masse moléculaire:404.43
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Blood Cancer Compound Library
HY-L079
-
Cancer Stem Cells Compound Library
HY-L135
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) Enitociclib
MoreVoir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
RNA Polymerase |
CDK9/CycT1 3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
52 nM
Compound: 32
|
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
|
[PMID: 34264057] |
| MOLM-13 | IC50 |
29 nM
Compound: 13; VIP152
|
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 38564299] |
| MOLM-13 | IC50 |
29 nM
Compound: 8; BAY-1251152
|
Antiproliferative activity against human MOLM-13 cells
Antiproliferative activity against human MOLM-13 cells
|
[PMID: 32866383] |
| MOLM-13 | IC50 |
42 nM
Compound: 32
|
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth in presence of fetal calf serum incubated for 96 hrs measured by celltiter-glo luminescent cell viability assay
|
[PMID: 34264057] |
| T-cell | IC50 |
3 nM
Compound: 53; BAY-1251152
|
Inhibition of CDK9/Cyclin T (unknown origin)
Inhibition of CDK9/Cyclin T (unknown origin)
|
[PMID: 35485642] |
Enitociclib effectively reduces the viability of a panel of human lymphoma cell lines, including the DLBCL cell lines SU-DHL-4 (IC50=43 nmol/L) and SU-DHL-10 (IC50=74 nmol/L)[1].
Enitociclib (0.25-1 μM; 4 h) induces transcriptomic changes dominated by significant downregulation in SU-DHL-4 and SU-DHL-10 DLBCL cell lines, including marked downregulation of novel targets PHF23 and TP53RK, as well as enrichment of the RNA polymerase II-mediated transcription pathway[1].
Enitociclib (0.6-800 nM; 6-48 h) potently inhibits the viability of primary mantle cell lymphoma (MCL) cells, MCL cell lines, and diffuse large B-cell lymphoma (DLBCL) cell lines, and induces caspase-3-dependent apoptosis in these cells, with an IC50 of 11.5-172.3 nM[2].
Enitociclib (12.5-200 nM; 96 h) significantly reduces the cell viability of multiple myeloma cell lines MM1.S, NCI-H929, OPM-2 and U266B1, with an IC50 ranging from 36 to 78 nM after 96 hours of treatment[3].
Enitociclib (0.5-1 μM; 1-24 h) inhibits phosphorylation of RNA Pol II CTD at Ser2/Ser5 sites in a dose- and time-dependent manner, induces apoptosis, and suppresses oncoprotein expression in NCI-H929 and OPM-2 multiple myeloma cell lines[3].
Enitociclib (25-500 nM; combined with paclitaxel) synergistically inhibits the growth of paclitaxel-resistant L3.6pl pancreatic cancer cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SU-DHL-4, SU-DHL-10 (DLBCL) cell lines
-
Concentration:0.25 μmol/L; 1 μmol/L
-
Incubation Time:4 h (treatment); up to 48 h post-washout (SU-DHL-4); up to 24 h post-washout (SU-DHL-10)
-
Result:Decreased p-Ser2 levels by 50% for up to 48 hours post-washout in SU-DHL-4 cells treated with 0.25 μmol/L.
Caused a greater extent of p-Ser2 inhibition that sustained for 48 hours post-washout in SU-DHL-4 cells treated with 1 μmol/L.
Achieved a 50% reduction of p-Ser2 for up to 24 hours post-washout in SU-DHL-10 cells treated with 1 μmol/L.
-
Cell Line:SU-DHL-4, SU-DHL-10 (DLBCL) cell lines
-
Concentration:0.25 μmol/L; 1 μmol/L
-
Incubation Time:4 h (treatment); up to 48 h post-washout
-
Result:Inhibited MYC and MCL1 mRNA levels by approximately 75% for 16 to 48 hours post-washout in SU-DHL-10 cells.
Maintained durable depletion of MYC and MCL1 mRNA levels over the 48-hour time course in SU-DHL-4 cells treated with 1 μmol/L.
-
Cell Line:MM1.S, NCI-H929, OPM-2, U266B1 multiple myeloma cell lines
-
Concentration:12.5-50 nM (in combination with other agents)
-
Incubation Time:96 h
-
Result:Exhibited synergistic effects (ZIP synergy score >10) with bortezomib in OPM-2 cells at 50 nM enitociclib and 1 nM bortezomib.
Showed synergistic effects with lenalidomide in MM1.S, NCI-H929, and U266B1 cells at 12.5 to 25 nM enitociclib and 313 nM to 5 μM lenalidomide.
Demonstrated synergistic effects with pomalidomide in NCI-H929 and U266B1 cells at 12.5 nM enitociclib and 12.5 to 50 nM pomalidomide.
Enitociclib (10 mg/kg; i.v.; twice a week) potently inhibits tumor growth and prolongs survival in JeKo-1 MCL cell line-derived xenografts in NSG mice (p < 0.0001 for both endpoints) without significant toxicity[2].
Enitociclib (15 mg/kg; i.v.; once per week) significantly reduces JJN-3 multiple myeloma tumor volumes in SCID/Beige mice, and a single dose (15 mg/kg; i.v.) transiently suppresses oncogene transcription and induces tumor apoptosis[3].
Enitociclib (15 mg/kg; i.v.; once per week) significantly reduces OPM-2 multiple myeloma tumor volumes in NOD/SCID mice, and enhances efficacy when combined with lenalidomide or bortezomib[3].
Enitociclib (10 mg/kg; i.v.; once weekly; 4 weeks) does not reduce tumor size as a single agent, but in combination with paclitaxel, it induces significant tumor shrinkage in a paclitaxel-resistant PDAC patient-derived xenograft model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C.B-17 SCID (female, 10-12 weeks old at study start)[1]
-
Dosage:5 mg/kg (mechanistic single dose); 10 mg/kg (i.v. once weekly for 3 weeks; mechanistic single dose); 15 mg/kg (i.v. once weekly for 3 weeks; mechanistic single dose)
-
Administration:i.v.; single dose (mechanistic studies); once weekly; 3 weeks (antitumor efficacy)
-
Result:Achieved a tumor growth inhibition (T/C) value of 0.19 on day 16/20, with sustained tumor growth control at 10 mg/kg once weekly.
Induced complete tumor regression during the 3-week treatment period, with a T/C value of 0.005 on day 16/20 at 15 mg/kg once weekly; tumors regrew after treatment cessation, but a second cycle of 15 mg/kg once weekly dosing induced tumor regression again.
Reduced RNA polymerase II Ser2 phosphorylation (p-Ser2) by >50% for 8 hours postdose; depleted MYC and MCL1 mRNA levels by 4 hours postdose, with depletion sustained for 8 hours at 5 mg/kg single dose.
Depleted p-Ser2 levels within 8 hours postdose; depleted MYC and MCL1 mRNA levels by 4 hours postdose, with depletion sustained for 8 hours; reduced Myc protein levels by 50% and Mcl-1 protein levels robustly within 4-8 hours postdose; increased cleaved PARP (apoptosis marker) levels postdose at 10 mg/kg and 15 mg/kg single dose.
-
Animal Model:NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (immunodeficient)[2]
-
Dosage:10 mg/kg
-
Administration:i.v.; twice a week
-
Result:Markedly inhibited tumor growth.
Significantly prolonged mouse survival.
Caused no significant body weight loss or other apparent adverse effects.\nEfficaciously inhibited PDX-1 tumor growth.
Caused no significant body weight loss.\nEfficaciously inhibited PDX-2 tumor growth.
Caused no significant body weight loss.\nEfficaciously inhibited PDX-3 tumor growth.
Caused no significant body weight loss.
-
Animal Model:NOD/SCID (gender not specified; injected subcutaneously with 5.0×106 OPM-2 MM cells)[3]
-
Dosage:15 mg/kg (monotherapy); 15 mg/kg (in combination with lenalidomide or bortezomib)
-
Administration:i.v.; once per week
-
Result:Significantly reduced OPM-2 tumor volumes compared with vehicle-treated mice as monotherapy.
Further enhanced antitumor efficacy compared with lenalidomide or bortezomib alone when combined with 50 mg/kg Lenalidomide (p.o.
daily) or 0.8 mg/kg Bortezomib (i.p.
twice weekly).
Chemical Information
-
CAS No. 1610408-97-3
-
Appearance Solid
-
Masse moléculaire 404.43
-
Formule C19H18F2N4O2S
-
Color Off-white to yellow
-
SMILES
COC1=C(C2=C(F)C=NC(NC3=CC(C[S@@](=O)(C)=N)=CC=N3)=C2)C=CC(F)=C1
-
Synonyms
(+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharm Sin B
2023 Sep;13(9):3694-3707. PMID: 37719386 -
Oncotarget
The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies. [Abstract]2023 Dec 20:14:997-1008. PMID: 38117531
Solvant et solubilité
DMSO : 113.3 mg/mL (280.15 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Frigault MM, et al. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023;3(11):2268-2279. [Content Brief]
[2]. Jiang V, et al. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Biomark Res. 2024;12(1):62. Published 2024 Jun 18. [Content Brief]
[3]. Tran S, et al. Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. Blood Neoplasia. 2024;2(1):100050. Published 2024 Oct 24. [Content Brief]
[4]. Hamdan FH, et al. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Gut. 2023;72(6):1174-1185. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4726 mL | 12.3631 mL | 24.7262 mL | 61.8154 mL |
| 5 mM | 0.4945 mL | 2.4726 mL | 4.9452 mL | 12.3631 mL | |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4726 mL | 6.1815 mL | |
| 15 mM | 0.1648 mL | 0.8242 mL | 1.6484 mL | 4.1210 mL | |
| 20 mM | 0.1236 mL | 0.6182 mL | 1.2363 mL | 3.0908 mL | |
| 25 mM | 0.0989 mL | 0.4945 mL | 0.9890 mL | 2.4726 mL | |
| 30 mM | 0.0824 mL | 0.4121 mL | 0.8242 mL | 2.0605 mL | |
| 40 mM | 0.0618 mL | 0.3091 mL | 0.6182 mL | 1.5454 mL | |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4945 mL | 1.2363 mL | |
| 60 mM | 0.0412 mL | 0.2061 mL | 0.4121 mL | 1.0303 mL | |
| 80 mM | 0.0309 mL | 0.1545 mL | 0.3091 mL | 0.7727 mL | |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2473 mL | 0.6182 mL |
Enitociclib Related Classifications
Cat. No.: HY-103019
Powered by Bioz
- Enitociclib
- 1610408-97-3
- (+)-BAY-1251152
- (+)-VIP152
- (S)-Enitociclib
- Drug Isomer
- CDK
- Apoptosis
- DNA/RNA Synthesis
- multiple myeloma
- mantle cell lymphoma
- MCL-1
- MYC-positive non-Hodgkin lymphoma
- caspase-3
- double-hit diffuse large B-cell lymphoma
- CDK9
- c-MYC
- RNA polymerase II
- cyclin-dependent kinase 9
- Inhibitor
- inhibitor
- inhibit